IL1A and neoplasm: For instance, MABp1, a true human moAb anti-IL-1α, showed disease control in patients with 18 different tumor types and its efficacy was further confirmed, in 2017, in a randomized, double-blind, placebo-controlled phase 3 study in a cohort of 333 advanced colorectal cancer patients [78].